Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Change in Receivables (2016 - 2025)

Ekso Bionics Holdings (EKSO) has disclosed Change in Receivables for 13 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Receivables rose 103.52% to $1.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$446000.0, a 122.67% decrease, with the full-year FY2025 number at -$446000.0, down 122.67% from a year prior.
  • Change in Receivables was $1.1 million for Q4 2025 at Ekso Bionics Holdings, down from $1.5 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $1.6 million in Q4 2021 to a low of -$2.2 million in Q2 2025.
  • A 5-year average of $221000.0 and a median of $357000.0 in 2023 define the central range for Change in Receivables.
  • Peak YoY movement for Change in Receivables: soared 485.71% in 2024, then crashed 520.56% in 2025.
  • Ekso Bionics Holdings' Change in Receivables stood at $1.6 million in 2021, then plummeted by 31.16% to $1.1 million in 2022, then plummeted by 112.6% to -$140000.0 in 2023, then skyrocketed by 485.71% to $540000.0 in 2024, then surged by 103.52% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for EKSO's Change in Receivables are $1.1 million (Q4 2025), $1.5 million (Q3 2025), and -$2.2 million (Q2 2025).